ly3298176 tirzepatide Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial Anti-Tirzepatide (LY3298176) Human IgG ELISA

In randomized controlled trials, participants taking oral semaglutide experienced average weight reductions ranging from 7% to 15% of their starting body weight over 68 weeks, depending on dosage and adherence

PringsheimTDavenportWMackieGWorthingtonIAubMChristieSNet al

Why stopping and starting can be risky For many patients, stopping is not really a choice

Lower HbA1c Levels By stimulating insulin secretion only when blood glucose levels are elevated and reducing the livers glucose output, Semaglutide stabilizes daily blood sugar spikes and safely lowers your long-term HbA1c

Pair injections with a targeted rehab program to protect gains

Med Sci Sports Exerc 2010;42:18091818